- Home
- RTB vs MCRB Comparison
RTB vs MCRB Comparison
Compare RTB & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RTB | MCRB |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.2M | 48.4M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | RTB | MCRB |
|---|---|---|
| Price | $17.00 | $4.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 88.6K | 77.8K |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.14 | $4.59 |
| 52 Week High | $20.75 | $29.98 |
Technical Indicators
Market Signals| Indicator | RTB | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 36.52 |
| Support Level | $13.32 | $4.59 |
| Resistance Level | $19.98 | $9.53 |
| Average True Range (ATR) | 2.27 | 0.39 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 35.89 | 21.70 |
Price Performance
Historical ComparisonAbout RTB RTB Digital Inc. Common Stock
RTB Digital Inc is focused on developing and operating a professional SaaS (Software as a Service) platform which hosts an exclusive coalition of professionally-managed online media channels. Its operations include software development, advertising and sponsorship sales, and onboarding third-party content operators (Platform Partners) to publish content on the platform.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.